Insulet (NASDAQ:PODD) PT Raised to $285.00

Insulet (NASDAQ:PODD) had its price target lifted by Piper Sandler from $230.00 to $285.00 in a research note published on Tuesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the medical instruments supplier’s stock.

PODD has been the subject of several other reports. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a neutral rating in a research report on Friday, August 9th. Barclays increased their price objective on Insulet from $200.00 to $220.00 and gave the stock an equal weight rating in a research note on Monday, August 12th. Redburn Atlantic started coverage on Insulet in a research report on Thursday, May 30th. They set a buy rating and a $235.00 target price on the stock. Canaccord Genuity Group reissued a buy rating and issued a $234.00 price target on shares of Insulet in a research report on Tuesday, July 23rd. Finally, BTIG Research cut their price objective on shares of Insulet from $270.00 to $250.00 and set a buy rating on the stock in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $229.21.

Insulet Stock Up 0.7 %

Shares of NASDAQ PODD opened at $237.68 on Tuesday. Insulet has a 12-month low of $125.82 and a 12-month high of $243.98. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The firm has a market cap of $16.66 billion, a PE ratio of 72.02, a P/E/G ratio of 4.31 and a beta of 1.21. The company’s fifty day simple moving average is $201.51 and its 200 day simple moving average is $187.32.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same quarter in the prior year, the business earned $0.38 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts forecast that Insulet will post 3.04 earnings per share for the current fiscal year.

Institutional Trading of Insulet

Several hedge funds have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. purchased a new stake in shares of Insulet during the 1st quarter worth approximately $29,000. International Assets Investment Management LLC bought a new position in Insulet during the second quarter valued at $32,000. UMB Bank n.a. increased its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in shares of Insulet in the fourth quarter valued at $40,000. Finally, CVA Family Office LLC lifted its position in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.